Print

Dicerna Pharmaceuticals Appoints Life Sciences Executive James B. Weissman to Chief Business Officer  
1/4/2012 7:27:07 AM

WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Dicerna), a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technologyâ„¢ and Dicer Substrate siRNA (DsiRNA) molecules, today announced the appointment of James B. Weissman to chief business officer. Mr. Weissman joins Dicerna with more than 25 years in the life sciences industry and will be responsible for corporate development, strategy and other operational functions.
//-->